Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 11/2023

20.10.2023 | Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Contraception and Cardiovascular Effects: What Should the Cardiologist Know?

verfasst von: Anhthu Trinh, Ankit Vyas, Anna Roselle, Dhivya Velu, Lekha Hota, Madhavi Kadiyala

Erschienen in: Current Cardiology Reports | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Cardiovascular disease (CVD) is the leading cause of death in women. This review highlights contraceptive options and their effects on the cardiovascular system (CVS). It provides guidance to cardiologists to make informed decisions regarding the safety of contraceptive use and cardiovascular risk stratification in the care of women of childbearing age.

Recent Findings

Approximately 44% of American women live with some type of CVD. Many women use hormonal contraception during their lifetime. It is imperative that cardiologists have a robust understanding of the forms of contraception in current use and their cardiovascular effects.

Summary

This contemporary review provides a comprehensive summary of available contraceptive methods to practicing cardiologists and aims to be used as a resource to guide cardiovascular specialists on contraception in the context of cardiovascular disease.
Literatur
1.
Long ME, Faubion SS, MacLaughlin KL, Pruthi S, Casey PM. Contraception and hormonal management in the perimenopause. J Womens Health 2002. 2015;24(1):3–10.
2.
Daniels K, Abma JC. Current contraceptive status among women aged 15–49: United States, 2017–2019. NCHS Data Brief. 2020;388:1–8.
3.
Skafar DF, Xu R, Morales J, Ram J, Sowers JR. Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab. 1997;82(12):3913–8.PubMed
4.
Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the transnational study on oral contraceptives and the health of young women. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 1999;4(2):67–73.CrossRef
5.
Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception. 1998;57(5):315–24.
6.
Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception. 2001;64(5):295–9.CrossRefPubMed
7.
• Brito M, Nobre F, Vieira C. Hormonal contraception and cardiovascular system. Arq Bras Cardiol. 2011;1(96):e81–9. This article highlights the physiological effects of endogenous and exogenous hormones on the cardiovascular system.CrossRef
8.
9.
Zhu X, Bonet B, Gillenwater H, Knopp RH. Opposing effects of estrogen and progestins on LDL oxidation and vascular wall cytotoxicity: implications for atherogenesis. Proc Soc Exp Biol Med Soc Exp Biol Med N Y N. 1999;222(3):214–21.CrossRef
10.
Jones DR, Schmidt RJ, Pickard RT, Foxworthy PS, Eacho PI. Estrogen receptor-mediated repression of human hepatic lipase gene transcription. J Lipid Res. 2002;43(3):383–91.CrossRefPubMed
11.
Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 1996;61(4):166–71.CrossRefPubMed
12.
Howard BV, Rossouw JE. Estrogens and cardiovascular disease risk revisited: the Women’s Health Initiative. Curr Opin Lipidol. 2013;24(6):493–9.CrossRefPubMedPubMedCentral
13.
Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523–34.CrossRefPubMed
14.
Salem JE, Dureau P, Bachelot A, Germain M, Voiriot P, Lebourgeois B, et al. Association of Oral contraceptives with drug-induced QT interval prolongation in healthy nonmenopausal women. JAMA Cardiol. 2018;3(9):877–82.CrossRefPubMedPubMedCentral
15.
Shekhar S, Agrawal A, Pampori A, Lak H, Windsor J, Ramakrishna H. Mortality in adult congenital heart disease: analysis of outcomes and risk stratification. J Cardiothorac Vasc Anesth. 2022;36(8 Pt B):3379–88.
16.
Baldwin MK, Jensen JT. Contraception during the perimenopause. Maturitas. 2013;76(3):235–42.CrossRefPubMed
17.
Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the United States, 2011–2013. Obstet Gynecol. 2017;130(2):366–73.CrossRefPubMedPubMedCentral
18.
Lindley KJ, BaireyMerz CN, Davis MB, Madden T, Park K, Bello NA, et al. Contraception and reproductive planning for women with cardiovascular disease: JACC focus seminar 5/5. J Am Coll Cardiol. 2021;77(14):1823–34.CrossRefPubMedPubMedCentral
19.
American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin No. 196: thromboembolism in pregnancy. Obstet Gynecol. 2018;132(1):e1–17.
20.
21.
Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of hormonal contraception with depression. JAMA Psychiat. 2016;73(11):1154–62.CrossRef
22.
23.
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-621.CrossRefPubMed
24.
Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109(2 Pt 1):339–46.CrossRefPubMed
25.
Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: a systematic review. Contraception. 2016;94(6):678–700.CrossRefPubMed
26.
Chiara Del Savio M, De Fata R, Facchinetti F, Grandi G. Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception. Expert Rev Clin Pharmacol. 2020;13(7):685–94.CrossRefPubMed
27.
Allen RH, Cwiak CA, Kaunitz AM. Contraception in women over 40 years of age. CMAJ Can Med Assoc J. 2013;185(7):565–73.CrossRef
28.
Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ. 2011;25(343): d6423.CrossRef
29.
Sugiura K, Kobayashi T, Ojima T. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res. 2016;137:11–6.CrossRefPubMed
30.
Reed S, Koro C, DiBello J, Becker K, Bauerfeind A, Franke C, et al. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 2021;26(6):439–46.
31.
von Stockum S, Becker K, Bauerfeind A, Franke C, Fruzzetti F, Calaf J, et al. NOMAC-E2 compares to LNG combined oral contraceptives in women over forty: real-world PRO-E2 study. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2023;39(1):2166032.CrossRef
32.
33.
•• Curtis KM. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep [Internet]. 2016 [cited 2023 Feb 28];65. Available from: https://​www.​cdc.​gov/​mmwr/​volumes/​65/​rr/​rr6503a1.​htm. This reference gives guidelines for various conditions, including cardiovascular conditions, and their recommendations for contraception which was one of the main purposes of this article. The table in this article was updated in 2020.
34.
Johnson-Mallard V, Kostas-Polston EA, Woods NF, Simmonds KE, Alexander IM, Taylor D. Unintended pregnancy: a framework for prevention and options for midlife women in the US. Womens Midlife Health. 2017;3:8.CrossRefPubMedPubMedCentral
35.
Antinori S, Gholami GH, Versaci C, Cerusico F, Dani L, Antinori M, et al. Obstetric and prenatal outcome in menopausal women: a 12-year clinical study. Reprod Biomed Online. 2003;6(2):257–61.CrossRefPubMed
36.
Dinger J, Möhner S, Heinemann K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol. 2013;122(4):800–8.CrossRefPubMed
37.
Grandi G, Barra F, Ferrero S, Facchinetti F. Estradiol in non-oral hormonal contraception: a “long and winding road.” Expert Rev Endocrinol Metab. 2019;14(3):153–5.CrossRefPubMed
38.
Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol. 2000;95(5):736–44.
39.
Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. Heart Br Card Soc. 2006;92(10):1520–5.CrossRef
40.
Swan L. Congenital heart disease in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2014;28(4):495–506.CrossRefPubMed
41.
Greutmann M, Pieper PG. Pregnancy in women with congenital heart disease. Eur Heart J. 2015;36(37):2491–9.CrossRefPubMed
42.
Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol. 1998;31(7):1650–7.CrossRefPubMed
43.
44.
Elkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. J Am Coll Cardiol. 2014;64(15):1629–36.CrossRefPubMed
45.
Hilfiker-Kleiner D, Haghikia A, Masuko D, Nonhoff J, Held D, Libhaber E, et al. Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur J Heart Fail. 2017;19(12):1723–8.CrossRefPubMed
46.
Yaméogo NV, Samadoulougou AK, Kagambèga LJ, Kologo KJ, Millogo GRC, Thiam A, et al. Maternal and fetal prognosis of subsequent pregnancy in black African women with peripartum cardiomyopathy. BMC Cardiovasc Disord. 2018;18(18):119.CrossRefPubMedPubMedCentral
Metadaten
Titel
Contraception and Cardiovascular Effects: What Should the Cardiologist Know?
verfasst von
Anhthu Trinh
Ankit Vyas
Anna Roselle
Dhivya Velu
Lekha Hota
Madhavi Kadiyala
Publikationsdatum
20.10.2023
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 11/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01981-9

Weitere Artikel der Ausgabe 11/2023

Current Cardiology Reports 11/2023 Zur Ausgabe

Congenital Heart Disease (RA Krasuski and G Fleming, Section Editors)

Novel Approaches to the Failing Congenital Heart

Interventional Cardiology (SR Bailey and T Helmy, Section Editors)

The Evolving Paradigm of Revascularization in Ischemic Cardiomyopathy: from Recovery of Systolic Function to Protection Against Future Ischemic Events

Diversity and Health Equity in Cardiology (AE Johnson, Section Editor)

Preventing Heart Failure Readmission in Patients with Low Socioeconomic Position

Cardio-Oncology (LA Baldassarre, Section Editor)

Advances in Screening for Radiation-Associated Cardiotoxicity in Cancer Patients

Cardiometabolic Disease (DM and CV) (CJ Lavie, Section Editor)

Obesity, Cardiorespiratory Fitness, and Cardiovascular Disease

Peripheral Vascular Disease (S Kinlay, Section Editor)

Endovascular Interventions for Peripheral Artery Disease: A Contemporary Review

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen